Name | PF-9363 |
---|---|
Synonyms | Benzenesulfonamide, 2,6-dimethoxy-N-[4-methoxy-6-(1H-pyrazol-1-ylmethyl)-1,2-benzisoxazol-3-yl]- |
Description | PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research of cancer[1][2]. |
---|---|
Related Catalog | |
Target |
KAT6A/KAT6B[1] |
In Vitro | PF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker[1]. PF-9363 leads to down regulation of a specific set of genes involved in ESR1 pathway, cell cycle and stem cell pathways. PF-9363 shows that the IC50 values for ZR75-1 and T47D are 0.3 nM and 0.9 nM[1]. Western Blot Analysis[1] Cell Line: ZR75-1, T47D and MCF7 cells Concentration: 0~1 μM Incubation Time: 1 day Result: Down-regulated the expression of H3K23Ac biomarker. |
In Vivo | PF-9363 shows strong anti-tumor activity in patient-derived xenograft models[1]. |
References |
[2]. WO2020254946 |
Molecular Formula | C20H20N4O6S |
---|---|
Molecular Weight | 444.46 |
Storage condition | -20°C |
Hazard Codes | Xn |
---|